Melodiol Global Health Ltd. (COPHF)

[AddyStone]

Creso Pharma $COPHF News 12 July 2021

Creso Pharma and Halucenex Life Sciences Inc. welcome Royal Commission into
veteran suicides and clinical studies into psychedelic treatments for addiction and
depression
Highlights
• Australian Federal Government Royal commission into veteran suicides established
after unanimous Australian government vote – highlights the need for treatment
alternatives
• Veteran and defence personnel suicide rates are nearly twice as high as the general
population upon return from service
• Creso and Halucenex commend the push to lower veteran’s suicide rates, which
currently stands at one every two weeks
• Halucenex’s key focus is on mental health treatment for veterans and suicide
prevention
• Royal commission will further highlight the large addressable mental illness market
and the urgent need for alternative treatments
• Halucenex is working with veterans to establish cures and alternative treatment
methods – this work will be continued post merger through The HighBrid Lab
• Creso Pharma and Halucenex also applaud clinical trials at Melbourne’s St. Vincent’s
Hospital to test psilocybin for terminally ill patients experiencing depression or
anxiety - further affirming the strength of Halucenex’s research-focused strategy
• Australian-first clinical trials also scheduled to begin in August at Sydney’s St.
Vincent’s Hospital to test the efficacy of psilocybin compounds in the treatment of
methamphetamine related addictions
• Re-emergence of COVID-19 has resulted in a sharp increase in mental health patients
throughout Australia with Beyond Blue experiencing a 64.8% surge in calls between
January 2021 and January 2019 (AIHW, 2021)
• Study on addiction treatment highlights broad applicability of psychedelic molecules
• Creso Pharma and Halucenex is strongly placed to assist into suicide prevention in
general and in particular war veterans.

Link:
https://files.marketindex.com.au/files/edms/CPH-Royal-Commission.pdf